4.7 Article

Glucose, Obesity, Metabolic Syndrome, and Diabetes Relevance to Incidence of Heart Failure

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 55, Issue 4, Pages 283-293

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2009.07.029

Keywords

glucose; obesity; heart failure; metabolic syndrome; diabetes

Funding

  1. NIH/NHLBI [1K23HL085097]
  2. Ahmanson Foundation
  3. GlaxoSmithKline
  4. Pfizer
  5. Novartis
  6. Bristol-Myers Squibb
  7. Sanofi-Aventis
  8. Merck

Ask authors/readers for more resources

Heart failure (HF) is common, results in poor clinical outcomes, and is associated with large health care costs. The incidence of HF continues to rise, with approximately 670,000 new cases per year and a 20% lifetime risk of HF for persons 40 years and older in the U. S. Risk factors for HF have been identified, and thus preventative strategies should have a positive effect on disease burden, morbidity, and mortality. Although coronary artery disease and hypertension have traditionally been considered among the most important modifiable risk factors for the development of HF, recent studies have highlighted the importance of increasingly prevalent metabolic risk factors: glucose, diabetes, obesity, and the metabolic syndrome. This report will present evidence for the link between glucose, diabetes, obesity, metabolic syndrome, and incident HF. Furthermore, we will discuss how risk factor modification and other preventive therapies may help curb the rising incidence of HF. (J Am Coll Cardiol 2010; 55: 283-93) (C) 2010 by the American College of Cardiology Foundation

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available